Ameriprise’s Applied Genetic Technologies Corporation AGTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-115,100
| Closed | -$31K | – | 4099 |
|
|
2022
Q3 | $31K | Sell |
115,100
-9,400
| -8% | -$4.1K | ﹤0.01% | 3912 |
|
|
2022
Q2 | $96K | Sell |
124,500
-3,200
| -3% | -$2.85K | ﹤0.01% | 3790 |
|
|
2022
Q1 | $137K | Sell |
127,700
-26
| -0% | -$47 | ﹤0.01% | 3813 |
|
|
2021
Q4 | $243K | Sell |
127,726
-3,574
| -3% | -$8.56K | ﹤0.01% | 3741 |
|
|
2021
Q3 | $395K | Sell |
131,300
-13,490
| -9% | -$48K | ﹤0.01% | 3482 |
|
|
2021
Q2 | $566K | Sell |
144,790
-4,801
| -3% | -$19.9K | ﹤0.01% | 3410 |
|
|
2021
Q1 | $758K | Buy |
149,591
+17,091
| +13% | +$88.7K | ﹤0.01% | 3247 |
|
|
2020
Q4 | $542K | Sell |
132,500
-7,700
| -5% | -$37.8K | ﹤0.01% | 3314 |
|
|
2020
Q3 | $681K | Sell |
140,200
-3,228
| -2% | -$17.6K | ﹤0.01% | 3131 |
|
|
2020
Q2 | $794K | Buy |
143,428
+15,800
| +12% | +$72.4K | ﹤0.01% | 3016 |
|
|
2020
Q1 | $419K | Buy |
+127,628
| New | +$672K | ﹤0.01% | 3190 |
|
|
2019
Q3 | – | Sell |
-10,128
| Closed | -$38K | – | 3791 |
|
|
2019
Q2 | $38K | Hold |
10,128
| – | – | ﹤0.01% | 3692 |
|
|
2019
Q1 | $42K | Hold |
10,128
| – | – | ﹤0.01% | 3656 |
|
|
2018
Q4 | $25K | Hold |
10,128
| – | – | ﹤0.01% | 3588 |
|
|
2018
Q3 | $74K | Hold |
10,128
| – | – | ﹤0.01% | 3642 |
|
|
2018
Q2 | $37K | Buy |
+10,128
| New | +$46.9K | ﹤0.01% | 3607 |
|
|
2018
Q1 | – | Sell |
-12,000
| Closed | -$43K | – | 3721 |
|
|
2017
Q4 | $43K | Buy |
+12,000
| New | +$45.3K | ﹤0.01% | 3598 |
|
Ameriprise's AGTC Position: Q4 2022 in Review
Ameriprise sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 115,100 shares — an estimated $31K sold.
Ameriprise first reported a position in AGTC in Q4 2017 and held it in 17 quarters. The position peaked at $794K in Q2 2020. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.
- Ameriprise reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
- Ameriprise sold 115,100 Applied Genetic Technologies Corporation shares in Q4 2022, an estimated $31K.
- Ameriprise first reported a position in Applied Genetic Technologies Corporation in Q4 2017 and held it in 17 quarters.
- Ameriprise's Applied Genetic Technologies Corporation position peaked at $794K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.
Based on Ameriprise's 13F filing for Q4 2022, filed 14 Feb 2023.